{
  "resourceType": "MedicationStatement",
  "id": "exa-medication-statement-caelyx",
  "meta": {
    "profile": [
      "https://www.vision-zero-oncology.de/fhir/StructureDefinition/pr-medication-statement"
    ]
  },
  "status": "active",
  "medicationCodeableConcept": {
    "coding": [
      {
        "code": "L01DB01",
        "system": "http://fhir.de/CodeSystem/bfarm/atc",
        "display": "Doxorubicin"
      }
    ]
  },
  "subject": {
    "reference": "Patient/example"
  },
  "effectiveDateTime": "2020-01-02T09:30:00+01:00",
  "dosage": [
    {
      "text": "Doxorubicin (Caelyx) 50 mg je Quadratmeter Koerperoberflaeche alle vier Wochen per intravenoeser Tropfinfusion",
      "timing": {
        "repeat": {
          "frequency": 1,
          "period": 4,
          "periodUnit": "wk"
        }
      },
      "route": {
        "coding": [
          {
            "code": "20045000",
            "system": "http://standardterms.edqm.eu",
            "display": "Intravenous use"
          }
        ]
      }
    }
  ]
}
